Title：

Osteoporosis Genetic Risk Prediction Using Bone Mineral Density Polygenic

Scores in Japanese: TMM CommCohort Study

Author：Yayoi Otsuka-Yamasaki[1,2]∗, Yoichi Sutoh[1,2], Tsuyoshi Hachiya[1,2], Motoki Nakao[1,3,4],

Shiori Minabe[1,2], Shohei Komaki[1,2], Hideki Ohmomo[1,2], Makoto Sasaki[1,5], and Atsushi

Shimizu[1,2]

[1] Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate

Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[2] Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate

Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[3] Department of Pharmacology, School of Medicine, Iwate Medical University, 1-1-1, Idaidori,

Yahaba 028-3694, Iwate, Japan

[4] Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of

Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan

[5] Division of Ultrahigh field MRI, Institute for Biomedical Sciences, Iwate Medical University,

1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

∗Corresponding author; Yayoi Otsuka-Yamasaki

Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate

Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

Tel; +81-019-651-5110

Mail to; yyayo@iwate-med.ac.jp

Conflict of Interest

31 TH is a board member of Genome Analytics Japan, Inc. The other authors declare no

32 conflicts of interest associated with this manuscript.

Abstract

Osteoporosis and fractures are major health concerns. We developed and validated a polygenic score (PGS) for osteoporosis in a Japanese population using heel quantitative ultrasound–derived T-scores. Genome-wide association study data from 12,371 participants in the Tohoku Medical Megabank Community-Based Cohort identified genome-wide significant loci, including *MBL2, TMEM135,* and *WNT16.* PGS models were constructed and evaluated using independent datasets for model selection (n = 1,419) and validation (n = 8,711). Adding the PGS to age and sex yielded modest improvements in discrimination but supported genetic risk stratification. Compared with the intermediate group, the lowest PGS quintile (bottom 20%, genetically high-risk) had higher odds of osteoporosis (OR = 1.22, 95% confidence interval (CI): 1.07–1.40), whereas the highest PGS quintile (top 20%, genetically low-risk) had lower odds of osteoporosis (OR = 0.85, 95% CI: 0.71–0.98). Prospective follow-up (mean 3.4 years) showed a similar gradient for incident osteoporosis, with higher incidence rate ratios in the high-risk group (1.42, 95% CI: 1.17–1.73) and lower incidence rate ratios in the low-risk group (0.70, 95% CI: 0.54–0.89). Age-stratified analyses revealed no significant age–PGS interaction and no differences in the slope of age-related T-score declines across genetic risk groups. Observed T-scores in young adults (20–44 years) and extrapolation to age 20 suggested lower bone status around peak bone mass among genetically high-risk individuals. These findings indicate that a Japanese-specific PGS can stratify osteoporosis risk and may help identify individuals at elevated genetic risk earlier in adulthood.

Introduction

Osteoporosis and osteoporotic fractures are significant public health concerns associated with impaired activities of daily living, diminished quality of life, and elevated mortality rates [1]. In older adults, fractures frequently necessitate prolonged care, thereby imposing economic burdens, including elevated expenditures for medical care and long-term care services [2, 3]. The estimated number of patients with osteoporosis in Japan is approximately 12.8 million, with approximately 193,400 hip fractures occurring annually [4].

Bone mineral density (BMD) is widely used as an indicator of bone mass, with heritability (the contribution of genetic factors) estimated at 50–80%, indicating a significant influence of genetic factors [3, 5]. Bone mass follows a characteristic life-course trajectory, with rapid accrual during childhood and puberty, reaching peak levels at 20–30 years of age, remaining relatively stable through midlife, and subsequently declining, particularly after menopause in women [1, 6]. As 40–60% of adult bone mass is formed during puberty, peak bone mass is considered a key determinant of the lifelong risk of developing osteoporosis.[6] Achieving and maintaining a higher peak bone mass during growth has been reported to provide a protective effect against osteoporosis in later life [1, 6, 7].

Advancements in genome-wide association studies (GWASs) have enabled the identification of numerous variants associated with BMD and fracture risk [5, 8]. Polygenic scores (PGS), derived from variants associated with BMD, have been developed to predict the genetic risk of osteoporosis and osteoporotic fractures [5, 9].

Recently, an estimated bone mineral density (eBMD) PGS derived from quantitative ultrasound (QUS) measurements was developed using data from the UK Biobank [5, 9]. The eBMD-based PGS has been evaluated for its predictive accuracy for osteoporosis and fractures in multiple cohorts, as it has shown a negative correlation with osteoporosis and fracture risk [5, 9, 10]. However, studies have consistently revealed that PGS derived from European populations exhibit reduced predictive performance in

non-European populations, including East Asians [10-12]. To address this limitation, PGS

models tailored to non-Europeans, including East Asians, should be developed [13-17].

Chen et al [17] have tested the multi-ancestry PGS, including Asians in a cohort of

Taiwanese people, and showed that it has moderate efficacy, but its performance is not

always optimal, and it emphasizes that the development of population-specific PGS is

essential in East Asian populations.

Concurrently, it has been shown that incorporating modifiable lifestyle factors into a

PGS framework may predict lifetime risk as well as guide targeted prevention strategies [18].

BMD is influenced by both basic and unchangeable environmental factors, such as sex, age,

and race, as well as modifiable factors such as calcium intake, smoking, alcohol

consumption, physical activity, and sun exposure [6,19]. Even individuals with a high genetic

risk for osteoporotic fractures can reduce their risk by adhering to healthy lifestyle habits in

European populations [19].

In this study, we developed a PGS for QUS-derived T-score in a Japanese

population using data from the Tohoku Medical Megabank (TMM), the largest genome

cohort in Japan [20–22], and evaluated its ability to predict osteoporosis risk. We assessed

genetic and environmental factors at baseline and followed participants over time to capture

incident osteoporosis using a longitudinal design. We stratified participants based on PGS,

examined its joint effects with non-modifiable and modifiable risk factors, and evaluated its

potential as a tool to inform osteoporosis prevention strategies in Japan.

Materials and Methods

Study population

TMM Project Community-Based Cohort (TMM CommCohort) has been described

in previous studies [20-22]. Participants who visited the evaluation centers in Miyagi and

Iwate Prefectures, were grouped into two primary cohorts: TMM18K and TMM9K,

respectively. The baseline survey was conducted from May 2013 to March 2016, and the

secondary survey, conducted 4 years after the baseline survey, was conducted from May

2017 to March 2020 as part of the ongoing follow-up.

The two cohorts were further divided into four groups based on genotyping with the

Axiom Japonica Array v2 (JPAv2) [23, 24] or NEO (JPANEO) [25] (TMM18K-JPAv2,

TMM18K-JPANEO, TMM9K-JPAv2, and TMM9K-JPANEO) (Figure 1 and Supplementary

Table S1). The TMM18K-JPAv2 cohort (n = 12,371) was used to perform QUS-derived

T-score GWAS, from which the variant weights for the PGS model were derived. The

TMM9K-JPANEO cohort (n = 1,419) was used to identify the best model for predicting

osteoporosis. The TMM9K-JPAv2 (n = 7,621) and TMM18K-JPANEO (n = 1,090) cohorts

were used for subsequent analyses. All four sample subgroups were independent from one

another.

Phenotype definition and measurement

Calcaneal QUS measurements were performed using a Benus device (NIHON

KOHDEN, Tokyo, Japan). The device-derived calcaneal T-score was calculated using the

manufacturer's young-adult reference (ages 20–40 years). We classified participants as

having osteoporosis when the device-derived QUS T-score was ≤ –2.5. Fracture cases were

identified based on the self-reported history of fractures in the lumbar spine, femur, wrist, or

humerus as documented by the participants in the questionnaire. Other anthropometric and

lifestyle factors, including alcohol intake and smoking history, were obtained from

self-reported questionnaires administered at baseline.

Participants who had smoked at least 100 cigarettes in their lifetime were defined

as having a "smoking" status. "High alcohol intake" was defined as the consumption of ≥ 30

g of alcohol per day. "Physical inactivity" was defined as engaging in leisure-time physical

activity less than three times weekly. "Obesity" was defined as a body mass index (BMI) of ≥

25 kg/m^2, calculated from height and weight measured at baseline, in accordance with the

local definition in Japan [26].

Study participants and validation cohort definitions

To evaluate the predictive performance of PGS, we used two independent validation cohorts: TMM9K-JPAv2 (validation cohort I) and TMM18K-JPANEO (validation cohort II). We conducted cross-sectional and prospective analyses based on baseline and follow-up survey data, respectively.

For the cross-sectional analysis, we excluded participants with (1) missing T-score values at baseline, (2) extreme baseline T-scores (outside the range –4.0 to +4.0 SD), or (3) missing essential covariates. The final sample included 7,609 participants in validation cohort I and 1,061 participants in validation cohort II (Supplementary Table S1).

For the prospective analysis, additional exclusion criteria were applied: (1) no participation in the follow-up survey; (2) baseline T-score ≤–2.5 SD; (3) history of fracture (lumbar spine, femur, wrist, or humerus); (4) self-reported history of osteoporosis at follow-up (because of unclear timing); and (5) extreme baseline T-scores (outside the range –4.0 to +4.0 SD). After these exclusions, the prospective subcohorts included 4,811 participants in validation cohort I and 581 participants in validation cohort II (Supplementary Table S1).

Genotyping and imputation

It was described in previous studies that the genotyping was performed using either JPAv2 [23, 24] or NEO (JPANEO) [25]. Participants with a call rate of < 0.95 and sex discrepancies between genotypic and cohort data were excluded. Genotypes that failed to meet the quality control criteria (call rate of < 0.99, Hardy–Weinberg equilibrium exact test P of $< 1 \times 10^{-5}$, and minor allele frequency of < 0.01) were also omitted. Pre-phasing and imputation were performed using SHAPEIT2 (r837) and IMPUTE4 (r300.3) with 3.5KJPNv2 haplotype reference panels [23, 28, 29]. Variant positions in the genome were based on the GRCh37 reference genome.

Genome-wide association analysis and annotations

To generate the PGS model, single nucleotide polymorphism (SNP) weights were estimated using a publicly available GWAS summary of TMM18K-JPAv2 from jMorp (ID: TGA000015; https://jmorp.megabank.tohoku.ac.jp/). Additional methodological details are available on the official website. In brief, GWAS was conducted with BOLT-LMM v2.3.2 [27]. Rank-based inverse normalization was applied to reduce the skewness and kurtosis in the T-score distribution. Age, sex, and the first 11 principal components were included as fixed effect covariates.

Annotation was performed using an in-house pipeline tailored to the Japanese population. The ToMMo 3.5KJPNv2 reference panel [28] was used to assign allele frequency information and dbSNP identifiers (rsIDs) to variants in the GWAS summary statistics. In addition, the gnomAD v2.1 dataset [29] was incorporated to ensure comprehensive rsID annotation and facilitate cross-population comparisons. Regional association plots were generated using LocusZoom (version 0.14.0) [30]. Linkage disequilibrium patterns and proxy variants were examined using LDproxy (LDlink, National Cancer Institute) [31] with the 1⌊KG EAS reference panel.

PGS construction and selection

Candidate models were constructed as described previously using three methods: LD pruning and thresholding (P+T), LDpred and polygenic risk score–continuous shrinkage (PRS-CS) [26, 32-34]. For the P+T method, 24 models were generated using different LD-pruning conditions using one of six parameters for p values (1, 0.5, 5×10^{-2}, 5×10^{-4}, 5×10^{-6}, and 5×10^{-8}) and one of four parameters of R^2 values (0.2, 0.4, 0.6, and 0.8). For LDpred, seven models were generated for each Spearman's rank correlation (ρ) value (1, 0.3, 0.1, 0.03, 0.01, 0.003, and 0.001). For PRS-CS, six models were generated for each φ value (1×10^{-1}, 1×10^{-2}, 1×10^{-4}, 1×10^{-6}, 1×10^{-8}, and "auto"). Individual PGSs were

calculated using PLINK 2.0 for each model and normalized to Z-scores.

In the selection step, TMM9K-JPANEO cohort was used as the dataset for model

selection. The model with the highest Spearman rank correlation coefficient (ρ) between the

age- and sex-adjusted T-scores and PGS Z-scores was selected.

Statistical analyses were performed using R (version 4.2.1). The receiver operating

characteristic (ROC) curve and area under the curve (AUC) for the PGS model was

estimated using the R package "pROC" (version 1.18.0). The AUCs between the models

were compared using DeLong's test.

PGS-based risk assessment and stratified analysis

The normalized PGS was divided into quintiles. Cross-sectional associations at

baseline were tested using linear regression for continuous outcomes and logistic

regression for binary outcomes, adjusting for sex and age. In addition, we conducted

stratified cross-sectional analyses by baseline age (< 65/≥ 65 years), sex, and major

osteoporosis-related risk factors (smoking, alcohol intake, physical activity, and obesity). For

these stratified analyses, participants were classified into three genetic risk groups: High

(Q1), Intermediate (Q2–Q4), and Low (Q5), using the Intermediate group as the reference

category in all comparisons.

For prospective analyses, participants without osteoporosis at baseline were

followed up for an average of 3.4 years. Because the exact event dates were unavailable,

person-time was approximated using the midpoint method: incident cases contributed half of

the follow-up duration, whereas non-cases contributed the full duration. Incidence rates per

1,000 person-years and cumulative incidence were estimated by genetic risk group with

exact 95% confidence intervals (CI).

Results from the two validation cohorts were pooled using the R package "meta"

(version 6.2-1). Fixed-effect models were used for the primary meta-analyses.

Between-cohort heterogeneity was assessed using Cochran's Q test and the I^2 statistic.

Random-effects models (DerSimonian–Laird method) were also fitted, and were examined

as sensitivity analyses to confirm the robustness of the results in the presence of substantial

heterogeneity (Q test $P < 0.05$ or $I^2 > 50\%$).

Ethical considerations

This research was conducted in accordance with the ethical principles outlined in

the Declaration of Helsinki. All participants provided written informed consent prior to their

enrollment. The study protocol was approved by the Institutional Review Board of Iwate

Medical University (approval ID: HG H25-2). Analyses using individual-level genomic and

phenotypic data were performed on a secure, standalone computational platform operated

by the Tohoku Medical Megabank Organization (ToMMo) at Tohoku University (ToMMo

Supercomputer System URL; https://sc.megabank.tohoku.ac.jp/).

Data Availability

The QUS-derived T-score GWAS summary has been published in jMorp

(https://jmorp.megabank.tohoku.ac.jp/gwas-studies/TGA000015). 3.5KJPNv2 is also

available on the jMorp website with a web interface. Owing to ethical considerations,

including the protection of participant privacy and prevention of unintended identification,

individual-level data from the TMM CommCohort Study are not publicly available. Access to

these cohorts may be granted upon reasonable request and is subject to approval by the

Ethics Committee of Iwate Medical University and the Materials and Information Distribution

Review Committee of the TMM Project. Researchers interested in accessing these datasets

should contact the corresponding author to initiate the request.

Results

Heritable factors for QUS-derived T-score

GWAS was conducted to identify variants associated with the T-score

(Supplementary Figure S1A). Variants in three independent loci were above the threshold

for the genome-wide significance ($P < 5 \times 10^{-8}$) (Supplementary Table S2). Notably,

792 variants were noted above the suggestive line ($P < 1 \times 10^{-5}$) (Supplementary Table

S3).

The three loci containing significant variants included genes that had been

reported in previous GWASs using QUS-derived T-scores as traits, such as Mannose

Binding Lectin 2 (*MBL2*), Transmembrane Protein 135 (*TMEM135*), and *Wnt* Family

Member 16 (*WNT16*) [3,5,8] (Supplementary Table S2). The UK Biobank GWAS summary

statistics and GWAS catalog study GCST006433 [5] were used for comparison.

As shown in Supplementary Table S2, at the *MBL2* locus, the lead variant in the

Japanese GWAS was rs71032654/rs200903639 (del(TA)$_9$CA > dup(TA)$_9$CA), a structural

indel. Notably, neither rs71032654 nor rs7908619 was present in the UK Biobank summary

statistics (Supplementary Table S2). LocusZoom plots showed recombination hotspots

exceeding 30 cM/Mb on either side of rs71032654 (Supplementary Figure S1C). Based on

the LDproxy results, rs71032654/rs200903639 showed only low LD with surrounding

variants (maximum R^2 = 0.0687), indicating that it may represent a distinct signal from

previously known tagged variants.

Variants in rs2451053 (C>T) in *TMEM135* and rs10254825 (A>G) in *WNT16* were

present in both the TMM and UK Biobank cohorts, indicating their similar biological effects

on BMD across populations.

Determination of the optimal PGS model for T-score measured with QUS

Based on the above GWAS summary, we constructed 37 candidate models to

calculate the PGS using three distinct methods (Figure 2A and Supplementary Table S4).

We determined that the PGS model established by PRS-CS with φ set to "auto" which was

composed of 1,012,314 variants, showed the strongest correlation with T-score levels after

adjusting for age and sex (Spearman's ρ = 0.147, $P = 2.94 \times 10^{-8}$). Therefore, this model

was selected and used for subsequent validation analyses as the best model.

Linear regression analysis of baseline T-scores against normalized PGS, adjusted

for sex and age, revealed a significant positive association in validation cohorts I (Estimate =

0.090, $P = 1.19 \times 10^{-15}$, Adjusted $R^2 = 0.237$), and II (Estimate = 0.098, $P = 0.001$, Adjusted

$R^2 = 0.204$) (Figure 2B and Supplementary Table S5).

Predictive performance and association of T-score PGS with osteoporosis

To investigate the predictive utility of PGS for osteoporosis, we evaluated the

performance of the model after including PGS in addition to sex and age. In validation

cohort I, there were 1,286 cases of osteoporosis out of 7,609, and in validation cohort II,

there were 233 cases of osteoporosis in 1,061 patients (Supplementary Table S6). In

validation cohorts I and II, the AUC values of the baseline model, including sex and age

were 0.726 (95% CI: 0.711–0.741) and 0.659 (95% CI: 0.622–0.696), respectively

(Supplementary Figure S2A and Supplementary Table S7). Adding PGS to the model

resulted in slight improvements, with AUC values of 0.728 (95% CI: 0.713–0.743) and 0.664

(95% CI: 0.627–0.701) in validation cohorts I and II, respectively (Supplementary Figure

S2A and Table S6).

We assessed the association between the T-score PGS and osteoporosis using

multivariable models in the two validation cohorts (Supplementary Figure S2B and

Supplementary Table S8). A fixed-effect model indicated minimal intercohort heterogeneity

for the PGS effect ($I^2 = 0\%$, Cochran's Q = 0.02, P for heterogeneity = 0.878). Accordingly,

we report the fixed-effect pooled estimate. Each 1.0-unit increase in the normalized PGS

was associated with 12% lower odds of osteoporosis (OR = 0.88, 95% CI: 0.83–0.94, $P =$

2.77×10^{-5}), indicating an inverse association between the T-score PGS and osteoporosis

risk. In addition, the odds of osteoporosis increased by 7% per year of age (OR = 1.07, 95%

CI: 1.07–1.08, $P = 3.03 \times 10^{-115}$), and was 1.84-fold higher in women than in men (OR = 1.84,

95% CI: 1.57–2.17, $P = 2.02 \times 10^{-13}$).

Osteoporosis risk prediction using T-score PGS

For further analysis, individuals in the validation cohorts were stratified into quintiles using the PGS. In the fixed-effect meta-analysis of the two validation cohorts, individuals in the lowest PGS quintile (Q1), which also had the lowest mean T-score (Supplementary Table S9), had a significantly increased risk of developing osteoporosis compared to the intermediate PGS quintile (Q3) (Table 1). Moreover, the OR for Q2 was significantly higher than that for Q3 (Table 1). In contrast, the highest PGS quintile (Q5), which had the highest mean T-score (Supplementary Table S9), was associated with a significantly lower risk of osteoporosis than Q3 (Table 1).

Osteoporosis genetic risk stratification by T-score PGS: Joint effects of age group, sex, and modifiable factors

To evaluate the influence of age and sex on the genetic risk of osteoporosis, we stratified participants at the clinically relevant threshold of 65 years of age, as recommended by osteoporosis guidelines for the Dual-energy X-ray Absorptiometry-based screening [35]. We compared the risk of osteoporosis across the genetic risk categories using individuals with intermediate (Q2–Q4) PGS as the reference group (Figure 3 and Supplementary Table S10). In the fixed-effect meta-analysis, younger individuals (< 65 years of age) with a lower genetic risk (Q5) showed significantly reduced odds of osteoporosis compared with the reference (OR = 0.74, 95% CI: 0.59–0.92, P = 0.006). Among older participants (≥ 65 years of age), those with a high genetic risk (Q1) exhibited significantly increased odds of osteoporosis compared to the reference (OR = 1.30, 95% CI: 1.04–1.62, P = 0.019). These findings indicate that a low genetic risk is more detectable in younger individuals, whereas a high genetic risk becomes evident in those aged ≥ 65 years.

Next, we performed additional stratification according to sex. In women, the pattern was consistent with the overall findings: those with low genetic risk (Q5) had a significantly

reduced odds of osteoporosis in the < 65 years of age group (OR = 0.74, 95% CI: 0.57–0.95,

P = 0.017), whereas those ≥ 65 years with high genetic risk (Q1) showed increased odds

compared with the reference group (OR = 1.42, 95% CI: 1.08–1.86, P = 0.012). However, in

men, no significant differences in osteoporosis odds were observed across genetic risk

categories within age groups.

Subsequently, we assessed the effects of modifiable lifestyle factors. Stratification

by established risk factors, including obesity, smoking, high alcohol intake, and physical

inactivity, did not show significant modification of genetic risk (Supplementary Figure S3 and

Supplementary Table S11).

Prospective cohort analysis

During the follow-up period, the corresponding person-years of observation for

validation cohorts I and II were 16,226.8 and 1,901.6, respectively. During the follow-up

period, 422 of 4,811 participants in validation cohort I and 116 of 581 in validation cohort II

developed new cases (Supplementary Table S12). In both cohorts, the cumulative incidence

of osteoporosis was highest in the genetic high-risk group (Q1) and lowest in the low-risk

group (Q5), with the incidence rate showing a similar trend (Table 2). Notably, in the

meta-analysis of IRR, the high-risk group (Q1) showed a significantly elevated risk

compared with the intermediate group (Q2-Q4), whereas the low-risk group (Q5) showed a

significantly reduced risk (Table 2).

Interaction of age with genetic risk of T-score and osteoporosis

We examined whether the predictive effect of PGS on osteoporosis varied with age.

Interaction terms for age × PGS were tested using logistic regression models with

osteoporosis as the outcome, including sex as a covariate. Notably, none of the interaction

terms reached statistical significance, indicating that the effect of PGS on osteoporosis was

consistent across different ages (Supplementary Table S13).

Next, we assessed the correlation between baseline age and T-score separately by

genetic risk group, comparing each group with the intermediate-risk group (Supplementary

Figure S4). No significant differences were observed in either the high- or low-risk groups,

and the slope of the association did not differ significantly between the groups

(Supplementary Table S14). These results indicate that the PGS was not associated with

the rate of age-related T-score decline.

Next, we used the fitted age–T-score regression lines to estimate group-specific

mean T-scores at age 20 years as an approximation of peak bone mass. When

extrapolating the linear regression model to age 20 years, the predicted mean T-score

differed significantly by genetic risk group: relative to the intermediate-risk group, the

low-risk group showed a positive deviation, whereas the high-risk group showed a negative

deviation (Supplementary Table S15). Consistent with this pattern, analyses of observed

T-scores at baseline among participants aged 20–44 years (young adult range) showed a

modest, non-significant trend toward lower values in the high-risk group and significantly

higher values in the low-risk group compared with the intermediate-risk group (Table 3).

These findings indicate that high-genetic risk primarily lowers the BMD trajectory from early

adulthood, instead of accelerating age-related bone loss, so that parallel declines over time

cause these individuals to reach the osteoporotic range earlier.

Discussion

Most polygenic models for bone traits have been developed using European

cohorts [5, 9, 10]. Because of ancestry differences, portability across populations remains a

key challenge, despite recent efforts toward cross-ancestry models [36, 37]. Although our

Japanese-specific model may not directly integrate into multi-ancestry frameworks, it

provides one of the first large-scale polygenic tools for osteoporosis risk in East Asians and

may serve as a valuable option in this population.

In the present study, we developed and validated a Japanese-specific PGS model

for osteoporosis in a large-scale cohort. Because of known ancestry differences in allele

frequencies, linkage disequilibrium structure, and environmental exposures, such

population-tailored scores are likely to perform better than PGSs derived exclusively from

European cohorts in East Asian populations. Our GWAS identified three loci, *MBL2,*

TMEM135, and *WNT16*, which have also been reported in previous GWASs in both

European and East Asian populations [5, 9, 38, 39]. The concordance of these loci across

populations, together with their involvement in bone-metabolism pathways [8], supports the

reliability of our GWAS and its use as a basis for constructing a PGS in East Asians.

The predictive performance of our model (AUC of approximately 0.73) was

comparable to that of European-derived models [5, 10]. Our model explained approximately

20–24% of the variance in QUS-derived T-scores, a proportion consistent with previous

large-scale studies using similar methods [9]. These results suggest that a

population-matched PGS can provide complementary, genetically anchored information for

risk stratification in East Asians. However, the incremental gain in discrimination beyond age

and sex is modest, indicating that the current model is best viewed as an adjunct for

stratification and hypothesis generation rather than a standalone clinical screening tool.

Although no statistically significant interaction between age and PGS was detected

in logistic regression models, subgroup analyses revealed clinically meaningful patterns.

Age-stratified odds ratios (ORs) indicated that individuals at high genetic risk had an

increased likelihood of osteoporosis in older age, even in the absence of a formal interaction

term. Together with the lack of differences in the slope of the age–T-score association

across genetic risk groups, these findings indicate that the PGS is not strongly associated

with the rate of age-related T-score decline.

Collectively, the observed age-stratified ORs and the contrasts in predicted and

observed T-scores in young adults support a model in which high-genetic risk primarily

lowers the bone mass trajectory from early adulthood, instead of accelerating age-related

bone loss. Using this model, parallel age-related declines across PGS groups mean that

individuals at high genetic risk are more likely to cross the osteoporotic threshold earlier in

later life. This interpretation is in line with previous observations that many BMD-associated

genetic variants exert stronger effects during the bone accrual phase in youth [7], and is

concordant with pediatric data showing that a BMD-related polygenic score is associated

with higher BMD and reduced fracture risk in childhood [40], as also highlighted by Fiscaletti

and Manousaki [41].

This interpretation is clinically relevant. Peak bone mass has long-term implications

for osteoporosis development, and individuals with a high genetic risk may inherently have a

lower bone mass established during early adulthood. Therefore, early identification and

intervention before the onset of bone loss may be the most effective. The absence of

statistical interaction should not be viewed as evidence against clinical relevance; instead,

our findings highlight the importance of age-stratified analyses and large-scale cohorts in

detecting subtle yet meaningful gene-environment dynamics.

This study had certain limitations. First, data on prior osteoporosis treatment were

unavailable, and participants undergoing therapy at baseline may not have been excluded.

Because osteoporosis treatment can increase or stabilize bone measures, inclusion of

treated individuals at baseline would be expected to attenuate associations and bias effect

estimates toward the null, making our observed gradients conservative. Second, recruitment

was limited to participants from health check-ups and community support centers in Miyagi

and Iwate Prefectures, potentially introducing a health-conscious selection bias [20-22]. This

may limit external generalizability; however, it is less likely to fully explain the monotonic risk

gradient observed across PGS strata and its consistency across independent datasets and

prospective follow-up. Third, key lifestyle factors (such as alcohol use, smoking, and

physical activity) were assessed by self-report, which may have affected accuracy. In

addition, most participants were middle-aged or older, and although lifestyle interventions

can increase or maintain BMD to some extent even in older adults, their effects are

generally considered small [1, 42]. This does not contrast with the importance of lifestyle,
but may instead reflect the limited plasticity of BMD once peak bone mass has been
established. Therefore, our findings support a prevention strategy that combines early
identification of genetically susceptible individuals with lifelong optimization of lifestyle
factors.

In conclusion, we established a polygenic score for osteoporosis risk in a Japanese
cohort and validated its performance. Our findings indicate that this score primarily reflects
genetically determined peak bone mass, such that high-risk individuals enter adulthood with
lower BMD levels and, despite similar rates of decline, reach the osteoporotic threshold
earlier. These observations support the use of polygenic information to identify susceptible
individuals at an early stage and to focus bone-preserving lifestyle strategies particularly
before the attainment of peak bone mass. However, further studies are required to
determine whether PGS-based interventions initiated in childhood or adolescence can
reduce the risk of osteoporosis. Although immediate clinical impact may be limited by
phenotype definition and cohort constraints, our findings provide population-specific
evidence that polygenic liability is linked to bone status established around peak bone mass,
supporting a life-course prevention framework for East Asian populations.

Acknowledgements

This study was supported by the Tohoku Medical Megabank (TMM) Project (Special
Account for the Reconstruction of the Great East Japan Earthquake) of the Ministry of
Education, Culture, Sports, Science and Technology (MEXT) and the Japan Agency for
Medical Research and Development (AMED; grant number JP23tm0124006). The
supercomputer system in the TMM Project (grant number JP21tm0424601) was used for
data analysis. YOY and AS were supported by the Japan Society for the Promotion of
Science (JSPS) KAKENHI Grant JP23K09696. During the preparation of this manuscript,

the authors used ChatGPT (OpenAI; GPT-4o) to assist with language editing, summarizing

relevant literature, and improving code readability and debugging.

Author contributions

Conceptualization: YOY, YS, TH, AS; Methodology: YOY, YS, TH, MN; Software: YOY, YS,

TH; Formal analysis: YOY, YS, TH; Data curation: YOY, YS; Writing—original draft: YOY;

Writing—review & editing: YOY, YS, TH, MN, SM, SK, HO, MS, AS.

Conflict of Interest

TH is a board member of Genome Analytics Japan, Inc. The other authors declare no

conflicts of interest associated with this manuscript.

Supplementary information

The Supplementary information is available at the Journal of Human Genetics website.

References

1.   Bouvard B, Annweiler C, Legrand E. Osteoporosis in older adults. Joint Bone Spine.

2021;88(3):105135. Epub 20210121. doi: 10.1016/j.jbspin.2021.105135

2.   Mori T, Komiyama J, Fujii T, Sanuki M, Kume K, Kato G, et al. Medical expenditures for

fragility hip fracture in Japan: A study using the nationwide health insurance claims

database. Arch Osteoporos. 2022;17(1):61. Epub 20220411. doi:

10.1007/s11657-022-01096-8

3.   Zhu X, Bai W, Zheng H. Twelve years of GWAS discoveries for osteoporosis and related

traits: advances, challenges and applications. Bone Res. 2021;9(1):23. Epub 20210429.

doi: 10.1038/s41413-021-00143-3

4.   Abe K, Inage K, Yoshimura K, Sato D, Yamashita K, Yamashita M, et al. Deaths caused

by osteoporotic fractures in Japan: An epidemiological study. J Orthop Sci.

2024;29(6):1477–82. Epub 20231118. doi: 10.1016/j.jos.2023.10.013

5.   Kim SK. Identification of 613 new loci associated with heel bone mineral density and a

polygenic risk score for bone mineral density, osteoporosis and fracture. PLoS One.

2018;13(7):e0200785. Epub 20180726. doi: 10.1371/journal.pone.0200785

6.   Hereford T, Kellish A, Samora JB, Reid Nichols L. Understanding the importance of peak

bone mass. JPOSNA. 2024;7:100031. Epub 20240405. doi:

10.1016/j.jposna.2024.100031

7.   Medina-Gomez C, Kemp JP, Trajanoska K, Luan J, Chesi A, Ahluwalia TS, et al.

Life-course genome-wide association study meta-analysis of total body BMD and

assessment of age-specific effects. Am J Hum Genet. 2018;102(1):88–102. doi:

10.1016/j.ajhg.2017.12.005

8.   Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas of genetic

influences on osteoporosis in humans and mice. Nat Genet. 2019;51(2):258–66. Epub

20181231. doi: 10.1038/s41588-018-0302-x

9.   Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp JP, et al.

Development of a polygenic risk score to improve screening for fracture risk: A genetic

risk prediction study. PLoS Med. 2020;17(7):e1003152. Epub 20200702. doi:

10.1371/journal.pmed.1003152

10.   Lu T, Forgetta V, Keller-Baruch J, Nethander M, Bennett D, Forest M, et al. Improved

prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Med.

2021;13(1):16. Epub 20210203. doi: 10.1186/s13073-021-00838-6

11.   Wu Q, Jung J. Genome-wide polygenic risk score for major osteoporotic fractures in

postmenopausal women using associated single nucleotide polymorphisms. J Transl

Med. 2023;21(1):127. Epub 20230216. doi: 10.1186/s12967-023-03974-2

12.　Kim DJ, Kang JH, Kim JW, Cheon MJ, Kim SB, Lee YK, et al. Evaluation of optimal

methods and ancestries for calculating polygenic risk scores in East Asian population.

Sci Rep. 2023;13(1):19195. Epub 20231106. doi: 10.1038/s41598-023-45859-w

13.　Lee SH, Lee SW, Ahn SH, Kim T, Lim KH, Kim BJ, et al. Multiple gene polymorphisms

can improve prediction of nonvertebral fracture in postmenopausal women. J Bone

Miner Res. 2013;28(10):2156–64. doi: 10.1002/jbmr.1955

14.　Lin YJ, Liang WM, Chiou JS, Chou CH, Liu TY, Yang JS, et al. Genetic predisposition to

bone mineral density and their health conditions in East Asians. J Bone Miner Res.

2024;39(7):929–41. doi: 10.1093/jbmr/zjae078

15.　Prive F, Aschard H, Carmi S, Folkersen L, Hoggart C, O'Reilly PF, et al. Portability of 245

polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups

from the same cohort. Am J Hum Genet. 2022;109(1):12–23. doi:

10.1016/j.ajhg.2021.11.008

16.　Li YM, Peng C, Zhang JG, Zhu W, Xu C, Lin Y, et al. Genetic risk factors identified in

populations of European descent do not improve the prediction of osteoporotic fracture

and bone mineral density in Chinese populations. Sci Rep. 2019;9(1):6086. Epub

20190415. doi: 10.1038/s41598-019-42606-y

17.　Chen JJ, Chen IC, Wei CY, Lin SY, Chen YM. Utilize polygenic risk score to enhance

fracture risk estimation and improve the performance of FRAX in patients with

osteoporosis. Arch Osteoporos. 2023;18(1):147. Epub 20231201. doi:

10.1007/s11657-023-01357-0

18.　Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk,

adherence to a healthy lifestyle, and coronary disease. N Engl J Med.

2016;375(24):2349–58. Epub 20161113. doi: 10.1056/NEJMoa1605086

19.　Yang YQ, Yu XH, Bo L, Lei SF, Deng FY. Genetic risk for osteoporosis and the benefit of

adherence to healthy lifestyles. Int J Public Health. 2022;67:1605114. Epub 20220913.

doi: 10.3389/ijph.2022.1605114

20.   Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, et al. The Tohoku Medical Megabank Project: Design and mission. J Epidemiol. 2016;26(9):493–511. Epub 20160702. doi: 10.2188/jea.JE20150268

21.   Hozawa A, Tanno K, Nakaya N, Nakamura T, Tsuchiya N, Hirata T, et al. Study profile of the Tohoku Medical Megabank community-based cohort study. J Epidemiol. 2021;31(1):65–76. Epub 20200111. doi: 10.2188/jea.JE20190271

22.   Hozawa A, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, et al. Progress report of the Tohoku Medical Megabank community-based cohort study: Study profile of the repeated center-based survey during second period in miyagi prefecture. J Epidemiol. 2024;34(9):434–43. Epub 20240731. doi: 10.2188/jea.JE20230241

23.   Yasuda J, Kinoshita K, Katsuoka F, Danjoh I, Sakurai-Yageta M, Motoike IN, et al. Genome analyses for the Tohoku Medical Megabank Project towards establishment of personalized healthcare. J Biochem. 2019;165(2):139–58. doi: 10.1093/jb/mvy096

24.   Minegishi N, Nishijima I, Nobukuni T, Kudo H, Ishida N, Terakawa T, et al. Biobank establishment and sample management in the Tohoku Medical Megabank Project. Tohoku J Exp Med. 2019;248(1):45–55. doi: 10.1620/tjem.248.45

25.   Sakurai-Yageta M, Kumada K, Gocho C, Makino S, Uruno A, Tadaka S, et al. Japonica Array NEO with increased genome-wide coverage and abundant disease risk SNPs. J Biochem. 2021;170(3):399–410. doi: 10.1093/jb/mvab060

26.   Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, et al. Healthy lifestyle practice correlates with decreased obesity prevalence in individuals with high polygenic risk: TMM CommCohort study. J Hum Genet. 2025;70(1):9–15. Epub 20240822. doi: 10.1038/s10038-024-01280-3

27.   Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-scale datasets. Nat Genet. 2018;50(7):906–8. doi: 10.1038/s41588-018-0144-6

28.   Tadaka S, Katsuoka F, Ueki M, Kojima K, Makino S, Saito S, et al. 3.5KJPNv2: an allele frequency panel of 3552 Japanese individuals including the X chromosome. Hum Genome Var. 2019;6:28. Epub 20190618. doi: 10.1038/s41439-019-0059-5

29.   Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–43. Epub 20200527. doi: 10.1038/s41586-020-2308-7

30.   Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et al. LocusZoom.js: interactive and embeddable visualization of genetic association study results. Bioinformatics. 2021;37(18):3017–8. doi: 10.1093/bioinformatics/btab186

31.   Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31(21):3555–7. Epub 20150702. doi: 10.1093/bioinformatics/btv402

32.   Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, et al. Genetic predisposition for immunoglobulin E production explains atopic risk in children: Tohoku Medical Megabank cohort study. Am J Hum Genet. 2025;112(8):1852–1863. Epub 20250721. doi: 10.1016/j.ajhg.2025.06.015

33.   Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10(1):1776. Epub 20190416. doi: 10.1038/s41467-019-09718-5

34.   Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, et al. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. Am J Hum Genet. 2015;97(4):576–92. doi: 10.1016/j.ajhg.2015.09.001

35.   Ward RJ, Roberts CC, Bencardino JT, Arnold E, Baccei SJ, Cassidy RC, et al. ACR Appropriateness Criteria® osteoporosis and bone mineral density. J Am Coll Radiol. 2017;14(5S):S189–S202. doi: 10.1016/j.jacr.2017.02.018

36.   Kelemen M, Vigorito E, Fachal L, Anderson CA, Wallace C. shaPRS: Leveraging shared genetic effects across traits or ancestries improves accuracy of polygenic scores. Am J Hum Genet. 2024;111(6):1006–17. Epub 20240503. doi: 10.1016/j.ajhg.2024.04.009

37.   Moreno-Grau S, Vernekar M, Lopez-Pineda A, Mas-Montserrat D, Barrabes M, Quinto-Cortes CD, et al. Polygenic risk score portability for common diseases across

genetically diverse populations. Hum Genomics. 2024;18(1):93. Epub 20240902. doi:

10.1186/s40246-024-00664-y

38.   Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A

cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet.

2021;53(10):1415–24. Epub 20210930. doi: 10.1038/s41588-021-00931-x

39.   Lu HF, Hung KS, Chu HW, Wong HS, Kim J, Kim MK, et al. Meta-analysis of

genome-wide association studies identifies three loci associated with stiffness index of

the Calcaneus. J Bone Miner Res. 2019;34(7):1275–83. Epub 20190319. doi:

10.1002/jbmr.3703

40.   Mitchell JA, Bradfield J, McCormack SE, Chesi A, Kalkwarf HJ, Lappe JM, et al. The

gSOS polygenic score is associated with bone density and fracture risk in childhood. J

Bone Miner Res. 2025. Epub 20251014. doi: 10.1093/jbmr/zjaf149

41.   Fiscaletti M, Manousaki D. Validation of a polygenic score for bone health-related

outcomes in childhood. J Bone Miner Res. 2025. Epub 20251010. doi:

10.1093/jbmr/zjaf146

42.   Bonjour JP, Gueguen L, Palacios C, Shearer MJ, Weaver CM. Minerals and vitamins in

bone health: the potential value of dietary enhancement. Br J Nutr.

2009;101(11):1581–96. Epub 20090401. doi: 10.1017/S0007114509311721

  Figure legends

Figure 1. Study design

Two TMM cohorts (9K and 18K) [20-22] were split using genotyping array, Axiom

Japonica Array v2 (JPAv2) [23, 24] and NEO (JPANEO) [25], into four independent

subgroups (TMM18K□JPAv2, TMM18K□JPANEO, TMM9K□JPAv2, and TMM9K□JPANEO).

QUS-derived T-score GWAS was conducted in TMM18K□JPAv2 to derive variant weights;

model selection was performed in TMM9K□JPANEO (Phase 1). The final PGS was

evaluated in two independent validation cohorts: I (TMM9K□JPAv2) and II

(TMM18K□JPANEO). Each cohort underwent (Phase 2) cross□sectional analysis at

baseline (excluding participants with missing T□scores, extreme baseline T-scores (outside

the range −4.0 to +4.0 SD), or missing covariates) and (Phase 3) prospective analysis using

follow□up data with additional exclusions (no follow□up, baseline T□score ≤ −2.5 SD,

fracture history, self□reported osteoporosis at follow□up, or extreme baseline T-scores

(outside the range −4.0 to +4.0 SD)). Final sample sizes were 7,609 and 1,061 for

cross□sectional, and 4,811 and 581 for prospective analyses in validation cohorts I and II,

respectively. All four subgroups were independent. Abbreviations: GWAS, genome-wide

association study; JPANEO, Japonica array NEO; JPAv2, Japonica array version 2; PGS,

polygenic score; PRS-CS, polygenic risk score—continuous shrinkage method; P+T,

pruning and thresholding method; SD, standard deviation; TMM, Tohoku Medical

Megabank.

Figure 2. Model selection of T-score PGSs

(A) Discriminative performance (ρ) of 37 candidate models generated using P+T,

LDpred, and PRS-CS methods. PRS-CS (φ = "auto") showed the highest ρ (ρ = 0.147, P =

2.94 × 10^{-8}). (B) Correlation of PGSs between the model selection cohort

(TMM9K-JPANEO) and validation cohorts I and II (TMM9K-JPAv2 and TMM18K-JPANEO).

Scatterplots show the relationship between normalized PGSs (x-axis) and age- and

sex-adjusted T-scores (y-axis). Dashed lines represent fitted linear regression lines with

95% CI. Color gradients indicate sample density. *P* values are from linear regression

analyses. Abbreviations: PGS, polygenic score; PRS-CS, polygenic risk score—continuous

shrinkage method; P+T, pruning and thresholding method.

Figure 3. Osteoporosis prevalence and ORs stratified by age-stratified genetic risk

groups

Participants were stratified by genetic risk (Q1: high, Q2–Q4: intermediate, Q5:

low) and age (< 65 or ≥ 65 years). The individuals with the intermediate [Q2–Q4] PGS group

served as reference. Osteoporosis prevalence (left and middle) and ORs (right) at baseline

were estimated using logistic regression adjusted for age and sex, with pooled results

obtained through fixed-effect meta-analysis. Bars indicate 95% CI. The bar color indicates

the status of genetic risk levels. † indicates a significant trend across genetic risk groups (P

< 0.05). * indicates a statistically significant pooled ORs from the fixed-effect meta-analysis

(P < 0.05). Abbreviations: PGS, polygenic score; Q, quintile.

Figure 1. Otsuka-Yamasaki et. al

Figure 2. Otsuka-Yamasaki et. al

Figure 3. Otsuka-Yamasaki et. al

Validation cohort I   Validation cohort II   Fixed-effect meta-analysis

Table 1. Osteoporosis prevalence and odds ratio stratified by PGS quintile in baseline study.

	PGS (quintile)	Number of subjects (n)	Number of cases (n)	Prevalence (%)	OR	95%CI Low	95%CI High	*P* value	*P* for trend	Cochran's Q	I^2 (%)	p_{het}
Validation cohort I (TMM9K-JPAv2, N=7,609)	Q1	1,522	289	19.0	1.24	1.02	1.51	**0.032**		–	–	–
	Q2	1,522	273	17.9	1.17	0.96	1.43	0.116		–	–	–
	Q3	1,521	240	15.8	1.00 (Reference)	–	–	–	**2.37E-04**	–	–	–
	Q4	1,522	263	17.3	1.06	0.87	1.30	0.556		–	–	–
	Q5	1,522	221	14.5	0.86	0.70	1.05	0.142		–	–	–
Validation cohort II (TMM18K-JPANEO, N=1,061)	Q1	213	49	23.0	1.02	0.64	1.62	0.940		–	–	–
	Q2	212	46	21.7	0.89	0.55	1.42	0.615		–	–	–
	Q3	212	49	23.1	1.00 (Reference)	–	–	–	0.490	–	–	–
	Q4	212	45	21.2	0.92	0.57	1.47	0.714		–	–	–
	Q5	212	44	20.8	0.83	0.52	1.33	0.443		–	–	–
Fixed-effect meta-analysis	Q1	–	–	–	1.22	1.07	1.40	**0.003**		0.64	0.0	0.72
	Q2	–	–	–	1.15	1.00	1.31	**0.047**		1.26	0.0	0.53
	Q3	–	–	–	1.00 (Reference)	–	–	–	–	–	–	–
	Q4	–	–	–	1.05	0.92	1.20	0.489		0.35	0.0	0.84
	Q5	–	–	–	0.85	0.74	0.98	**0.027**		0.01	0.0	0.99

Odds ratios for osteoporosis at baseline were estimated using logistic regression adjusted for age and sex. Pooled estimates were obtained using fixed-effects meta-analysis. Bold indicates statistical significance ($P < 0.05$). Abbreviations: *CI*, confidence interval; I^2, percentage of variation due to heterogeneity; *JPANEO*, Japonica Array NEO; *JPAv2*, Japonica Array version 2; OR, odds ratio; P_{het}, *P* value for heterogeneity; *PGS*, polygenic score; *TMM*, Tohoku Medical Megabank. Q indicates quintile.

Table 2. Incidence and risk estimates of osteoporosis by PGS-based genetic risk group in the follow-up study.

	Genetic risk [quintile]	n at risk	Cases	Person-years	Cumulative incidence (%)	95%CI Low	95%CI High	Incidence rate (/1,000 PY)	95%CI Low	95%CI High	IRR	95%CI Low	95%CI High	P value	Cochran's Q	I^2 (%)	P_{het}
Validation cohort I TMM9K-JPAv2 (N=4,811)	High [Q1]	914	116	3032.7	12.7	10.6	15.0	38.2	31.6	45.9	1.45	1.16	1.80	**9.30E-04**	–	–	–
	Intermediate [Q2 - Q4]	2,910	260	9815.6	8.9	7.9	10.0	26.5	23.4	29.9	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	987	66	3378.5	6.7	5.2	8.4	19.5	15.1	24.9	0.74	0.57	0.97	**0.030**	–	–	–
Validation cohort II TMM18K-JPANEO (N=581)	High [Q1]	115	30	357.4	26.1	18.3	35.1	83.9	56.6	119.8	1.33	0.87	2.03	0.188	–	–	–
	Intermediate [Q2 - Q4]	356	74	1161.1	20.8	16.7	25.4	63.7	50.0	80.0	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	110	12	383.0	10.9	5.8	18.3	31.3	16.2	54.7	0.51	0.28	0.94	**0.030**	–	–	–
Fixed-effect meta-analysis	High [Q1]	–	–	–	–	–	–	–	–	–	1.42	1.17	1.73	**3.89E-04**	0.12	0.0	0.73
	Intermediate [Q2 - Q4]	–	–	–	–	–	–	–	–	–	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	–	–	–	–	–	–	–	–	–	0.70	0.54	0.89	**0.004**	1.23	18.6	0.27

IRR for incident osteoporosis during the follow-up period was estimated using logistic regression adjusted for age and sex.

Pooled estimates were obtained using fixed-effect meta-analysis. Bold indicates statistical significance ($P < 0.05$).

Abbreviations: *CI*, confidence interval; I^2, percentage of variation due to heterogeneity; *IRR*, incidence rate ratios; *JPANEO*,

Japonica Array NEO; *JPAv2*, Japonica Array version 2; P_{het}, P value for heterogeneity; *PGS*, polygenic score; *PY*, person-years; *TMM*, Tohoku Medical Megabank.

Table 3. Differences in observed T-score at baseline (age 20-44, young adult range) for high- and low-generic risk groups versus the intermediate-risk group (Q2–Q4).

	Genetic risk [quintile]	n	Observed T-score		Difference in observed T-score vs Intermediate group (group − intermediate)							
			Mean	SD	Mean	SE	95%CI		P value	Cochran's Q	I² (%)	P_het
							Low	High				
Validation cohort I (TMM9K-JPAv2, N=7,609)	High [Q1]	314	-0.831	1.140	-0.135	0.076	-0.283	0.014	**0.038**	–	–	–
	Intermediate [Q2 - Q4]	898	-0.696	1.193	–	–	–	–	–	–	–	–
	Low [Q5]	279	-0.439	1.184	0.257	0.081	0.098	0.417	**0.001**	–	–	–
Validation cohort II (TMM18K-JPANEO, N=1,061)	High [Q1]	48	-0.891	1.031	-0.118	0.186	-0.487	0.251	0.264	–	–	–
	Intermediate [Q2 - Q4]	122	-0.773	1.236	–	–	–	–	–	–	–	–
	Low [Q5]	42	-0.831	1.230	-0.059	0.220	-0.498	0.380	0.605	–	–	–
Fixed-effect meta-analysis	High [Q1]	–	–	–	-0.133	0.070	-0.270	0.005	0.059	0.01	0	0.93
	Low [Q5]	–	–	–	0.219	0.076	0.070	0.369	**0.004**	1.81	44.8	0.18

The differences in observed T-score values at age 20-44 (young adult range) for the high- and low-risk groups compared with the intermediate-risk group (reference). Pooled estimates were obtained using fixed-effect meta-analysis. Bold indicates statistical significance (p < 0.05). Abbreviations: CI, confidence interval; I^2, percentage of variation due to

heterogeneity; *JPANEO*, Japonica Array NEO; *JPAv2*, Japonica Array version 2; P_{het}, P value for heterogeneity; *PGS*,

polygenic score; *TMM*, Tohoku Medical Megabank.